Marinus Pharmaceuticals Management
Management criteria checks 2/4
Marinus Pharmaceuticals' CEO is Scott Braunstein, appointed in Aug 2019, has a tenure of 4.75 years. total yearly compensation is $3.21M, comprised of 20.2% salary and 79.8% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $162.06K. The average tenure of the management team and the board of directors is 3.5 years and 4.1 years respectively.
Key information
Scott Braunstein
Chief executive officer
US$3.2m
Total compensation
CEO salary percentage | 20.2% |
CEO tenure | 4.8yrs |
CEO ownership | 0.2% |
Management average tenure | 3.5yrs |
Board average tenure | 4.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$3m | US$650k | -US$141m |
Sep 30 2023 | n/a | n/a | -US$134m |
Jun 30 2023 | n/a | n/a | -US$28m |
Mar 31 2023 | n/a | n/a | -US$35m |
Dec 31 2022 | US$3m | US$591k | -US$20m |
Sep 30 2022 | n/a | n/a | -US$14m |
Jun 30 2022 | n/a | n/a | -US$105m |
Mar 31 2022 | n/a | n/a | -US$91m |
Dec 31 2021 | US$4m | US$574k | -US$99m |
Sep 30 2021 | n/a | n/a | -US$88m |
Jun 30 2021 | n/a | n/a | -US$84m |
Mar 31 2021 | n/a | n/a | -US$76m |
Dec 31 2020 | US$4m | US$556k | -US$76m |
Sep 30 2020 | n/a | n/a | -US$74m |
Jun 30 2020 | n/a | n/a | -US$72m |
Mar 31 2020 | n/a | n/a | -US$69m |
Dec 31 2019 | US$2m | US$305k | -US$54m |
Sep 30 2019 | n/a | n/a | -US$49m |
Jun 30 2019 | n/a | n/a | -US$46m |
Mar 31 2019 | n/a | n/a | -US$43m |
Dec 31 2018 | US$210k | n/a | -US$37m |
Compensation vs Market: Scott's total compensation ($USD3.21M) is above average for companies of similar size in the UK market ($USD349.23K).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
CEO
Scott Braunstein (60 yo)
4.8yrs
Tenure
US$3,214,100
Compensation
Dr. Scott N. Braunstein, M.D., serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He served as Director at Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, In...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Chairman | 4.8yrs | US$3.21m | 0.20% $ 162.1k | |
COO, CFO & Treasurer | 3.1yrs | US$1.44m | 0.023% $ 19.2k | |
Chief Medical Officer | 4.6yrs | US$1.37m | 0.023% $ 18.7k | |
Chief Scientific Officer | no data | no data | no data | |
Senior VP of Investor Relations | less than a year | no data | no data | |
Senior VP | 3.9yrs | no data | 0.0057% $ 4.7k | |
Director of Corporate Communications & Investor Relations | less than a year | no data | no data | |
Chief Regulatory & Quality Assurance Officer | no data | no data | no data | |
Chief Business Officer | no data | no data | no data | |
Chief Commercial Officer | 3.5yrs | no data | 0.018% $ 14.5k | |
Senior Vice President of Chemistry | no data | no data | no data | |
Senior Vice President of Development | no data | no data | no data |
3.5yrs
Average Tenure
60yo
Average Age
Experienced Management: 0JYL's management team is considered experienced (3.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Chairman | 5.7yrs | US$3.21m | 0.20% $ 162.1k | |
Lead Independent Director | 15.4yrs | US$202.52k | 0.025% $ 20.9k | |
Independent Director | 4.4yrs | US$162.52k | 0.0036% $ 3.0k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 7.7yrs | US$160.02k | 0.0044% $ 3.7k | |
Independent Director | 3.2yrs | US$154.74k | 0.0050% $ 4.2k | |
Independent Director | 3.8yrs | US$157.52k | 0.0031% $ 2.5k | |
Independent Director | 1.3yrs | US$249.21k | no data | |
Independent Director | 1.1yrs | US$304.81k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
4.1yrs
Average Tenure
60.5yo
Average Age
Experienced Board: 0JYL's board of directors are considered experienced (4.1 years average tenure).